对吴等人的回应——马来西亚和香港婴儿肺炎球菌疫苗接种的成本效益分析
Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.
作者信息
Varghese Lijoy, Mungall Bruce, Zhang Xu-Hao, Hoet Bernard
机构信息
a GSK Vaccines , Singapore , Singapore.
b GSK Vaccines , Wavre , Belgium.
出版信息
Hum Vaccin Immunother. 2016 Oct 2;12(10):2675-2680. doi: 10.1080/21645515.2016.1192738. Epub 2016 Jul 26.
Abstract
A recently published paper that assessed the comparative cost-effectiveness of the 2 pneumococcal conjugate vaccines (PCVs) in Malaysia and Hong Kong reported that the 13-valent PCV vaccine (PCV13) is a better choice compared to the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV or PCV10) from both a payer and societal perspective as well as under various scenarios. However, the analysis relied on a large number of assumptions that were either erroneous or did not take into account the most recent body of evidence available. A rigorous evaluation of the underlying assumptions is necessary to present a fair and balanced analysis for decision-making.
摘要
最近发表的一篇评估两种肺炎球菌结合疫苗（PCV）在马来西亚和香港的比较成本效益的论文报告称，从支付方和社会角度以及在各种情况下，13价肺炎球菌结合疫苗（PCV13）比10价肺炎球菌非分型流感嗜血杆菌蛋白D结合疫苗（PHiD-CV或PCV10）是更好的选择。然而，该分析依赖于大量要么错误要么未考虑到最新可得证据的假设。对这些潜在假设进行严格评估对于提供公平和平衡的决策分析是必要的。
相似文献
1
Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.对吴等人的回应——马来西亚和香港婴儿肺炎球菌疫苗接种的成本效益分析
Hum Vaccin Immunother. 2016 Oct 2;12(10):2675-2680. doi: 10.1080/21645515.2016.1192738. Epub 2016 Jul 26.
2
Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.马来西亚和香港地区婴儿普遍常规接种肺炎球菌疫苗的成本效益分析。
Hum Vaccin Immunother. 2016;12(2):403-16. doi: 10.1080/21645515.2015.1067351.
3
A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.新西兰全民推广使用 10 价肺炎球菌-无荚膜流感嗜血杆菌蛋白 D 结合疫苗（PHiD-CV）与 13 价肺炎球菌结合疫苗（PCV13）的成本效益分析
Appl Health Econ Health Policy. 2018 Jun;16(3):331-345. doi: 10.1007/s40258-018-0387-5.
4
A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.在突尼斯国家免疫规划背景下，对 PHiD-CV 与 PCV13 的成本效益进行分析。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2079305. doi: 10.1080/21645515.2022.2079305. Epub 2022 Jun 15.
5
Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.肺炎球菌结合疫苗的总体效果：在意大利对婴儿进行免疫接种中 PHiD-CV 和 PCV-13 的经济分析。
Hum Vaccin Immunother. 2017 Oct 3;13(10):2307-2315. doi: 10.1080/21645515.2017.1343773. Epub 2017 Jul 12.
6
Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.韩国儿童肺炎球菌结合疫苗（PHiD-CV）接种的成本效益分析。
Hum Vaccin Immunother. 2018 Jan 2;14(1):85-94. doi: 10.1080/21645515.2017.1362513. Epub 2017 Nov 8.
7
Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.秘鲁儿童三种肺炎球菌结合疫苗的成本效果和成本效用分析。
BMC Public Health. 2013 Oct 30;13:1025. doi: 10.1186/1471-2458-13-1025.
8
Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.10价肺炎球菌非分型流感嗜血杆菌蛋白D结合疫苗（PHiD-CV）对马里第二年儿童进行2剂补种疫苗接种的安全性、反应原性和免疫原性：一项开放性研究的结果
Hum Vaccin Immunother. 2015;11(9):2207-14. doi: 10.1080/21645515.2015.1016679.
9
Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.建立新疫苗对肺炎球菌和非典型流感嗜血杆菌疾病影响的模型：一种新的模拟模型。
Clin Ther. 2009 Oct;31(10):2152-69. doi: 10.1016/j.clinthera.2009.10.014.
10
Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.10价肺炎球菌结合疫苗对巴西圣保罗儿童鼻咽部肺炎链球菌和流感嗜血杆菌携带情况的影响。
Vaccine. 2016 Nov 4;34(46):5604-5611. doi: 10.1016/j.vaccine.2016.09.027. Epub 2016 Sep 28.
引用本文的文献
1
Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.迈向不丹引入肺炎球菌结合疫苗：一项成本效用分析以确定最佳政策选择。
Vaccine. 2018 Mar 20;36(13):1757-1765. doi: 10.1016/j.vaccine.2018.02.048. Epub 2018 Feb 22.
2
Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.马来西亚采用2+1程序的吸附无细胞百白破-脊髓灰质炎-乙型肝炎联合疫苗（PHiD-CV）进行全民大规模疫苗接种计划的成本效益分析。
Cost Eff Resour Alloc. 2017 Aug 22;15:17. doi: 10.1186/s12962-017-0079-2. eCollection 2017.
3
Reply to Varghese et al.'s response to Wu et al. - "Cost effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong".对瓦尔吉斯等人对吴等人的回应——“马来西亚和香港婴儿肺炎球菌疫苗接种的成本效益分析”的回复。
Hum Vaccin Immunother. 2016 Oct 2;12(10):2681-2684. doi: 10.1080/21645515.2016.1209279.
本文引用的文献
1
Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme.肺炎球菌蛋白 D 结合疫苗（PHiD-CV）对马来西亚国家免疫规划的经济影响。
Value Health Reg Issues. 2014 May;3:146-155. doi: 10.1016/j.vhri.2014.04.008. Epub 2014 May 21.
2
Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.13 价肺炎球菌结合疫苗预防美国儿童侵袭性肺炎球菌病的效果：一项匹配病例对照研究。
Lancet Respir Med. 2016 May;4(5):399-406. doi: 10.1016/S2213-2600(16)00052-7. Epub 2016 Mar 14.
3
The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014.2001年至2014年间法国儿童实施肺炎球菌结合疫苗的多方面影响。
Hum Vaccin Immunother. 2016;12(2):277-84. doi: 10.1080/21645515.2015.1116654.
4
Decreased Incidence of Respiratory Infections in Children After Vaccination with Ten-valent Pneumococcal Vaccine.十价肺炎球菌疫苗接种后儿童呼吸道感染发病率降低
Pediatr Infect Dis J. 2015 Dec;34(12):1385-90. doi: 10.1097/INF.0000000000000899.
5
The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials.各剂次肺炎球菌结合疫苗初种对鼻咽部携带的短期影响：随机对照试验的系统评价和荟萃分析
Vaccine. 2016 Feb 3;34(6):703-13. doi: 10.1016/j.vaccine.2015.12.048. Epub 2015 Dec 29.
6
Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands.荷兰引入10价肺炎球菌结合疫苗3年后的侵袭性肺炎球菌病
Emerg Infect Dis. 2015 Nov;21(11):2040-4. doi: 10.3201/eid2111.140780.
7
Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.转换为10价肺炎球菌结合疫苗后，非分型流感嗜血杆菌引起的中耳感染减少，但肺炎链球菌引起的中耳感染未减少。
BMC Pediatr. 2015 Oct 19;15:162. doi: 10.1186/s12887-015-0483-8.
8
Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.马来西亚和香港地区婴儿普遍常规接种肺炎球菌疫苗的成本效益分析。
Hum Vaccin Immunother. 2016;12(2):403-16. doi: 10.1080/21645515.2015.1067351.
9
Vaccination Coverage and Compliance with Three Recommended Schedules of 10-Valent Pneumococcal Conjugate Vaccine during the First Year of Its Introduction in Brazil: A Cross-Sectional Study.巴西引入10价肺炎球菌结合疫苗第一年的接种覆盖率及三种推荐接种程序的依从性：一项横断面研究
PLoS One. 2015 Jun 10;10(6):e0128656. doi: 10.1371/journal.pone.0128656. eCollection 2015.
10
Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.三种肺炎球菌结合疫苗预防加拿大魁北克侵袭性肺炎球菌疾病的有效性
Vaccine. 2015 May 28;33(23):2684-9. doi: 10.1016/j.vaccine.2015.04.005. Epub 2015 Apr 15.
Zotero 插件